+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
5-Alpha Reductase Deficiency Market - Global Forecast 2026-2032- Product Image
5-Alpha Reductase Deficiency Market - Global Forecast 2026-2032- Product Image
New

5-Alpha Reductase Deficiency Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 187 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6014980
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The 5-Alpha Reductase Deficiency Market is undergoing structural shifts as advances in diagnostics, pharmacology, and digital health converge to redefine care pathways and access models for stakeholders worldwide.

Market Snapshot: 5-Alpha Reductase Deficiency Market

In 2025, the market achieved a valuation of USD 1.41 billion, growing to USD 1.56 billion by 2026, and is forecast to expand at a compound annual growth rate (CAGR) of 11.25%, reaching USD 2.98 billion by 2032. Growth is driven by increasing clinical recognition, integration of genetic diagnostics, and expanded therapeutic options.

Scope & Segmentation

This report provides a comprehensive analysis across critical dimensions influencing market direction and operational decision-making:

  • Product Categories: Dutasteride, finasteride, and other therapeutics for androgen metabolism disorders.
  • Formulation Types: Capsule (immediate and extended release), solution (concentrated and standard), tablet (immediate and extended release).
  • Routes of Administration: Oral and topical therapies.
  • Distribution Models: Hospital pharmacy (private and public), online pharmacies (branded and third-party), retail pharmacy (chain and independent).
  • End User Settings: Hospitals (general and specialty units), clinics (urology and dermatology), and home care.
  • Age Groups: Adult, geriatric, and pediatric patients with tailored dosing and monitoring needs.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific.
  • Enabling Technologies: Molecular diagnostics, digital health solutions, next-generation manufacturing, and telemedicine.

Key Takeaways: Strategic Insights for Decision-Makers

  • Modern management of five-alpha reductase deficiency requires multidisciplinary collaboration among endocrinologists, urologists, dermatologists, and genetic counselors.
  • Widespread adoption of advanced molecular diagnostics accelerates patient classification and makes personalized care plans more accessible.
  • Segment-specific formulation choices—such as pediatric-friendly solutions and age-adapted tablets—are increasingly critical to adherence and real-world outcomes.
  • Digital health platforms enable remote monitoring and virtual consultations, supporting continuity of care across disparate geographies and resource levels.
  • Stakeholder advocacy, including patient groups and informed families, is advancing shared decision-making and highlighting unmet needs in the care pathway.
  • Regional dynamics and regulatory variability require customized commercial, distribution, and regulatory strategies for market success.

Tariff Impact on Supply Chain and Clinical Continuity

The 2025 tariff reforms affecting pharmaceutical ingredients, medical devices, and related supplies have reshaped procurement strategies and supply networks. Manufacturers adjusted to increased landed costs and lengthened lead times by diversifying suppliers, reassessing contract terms, and developing regional manufacturing hubs. Healthcare providers responded by identifying clinically equivalent alternatives and adapting procurement practices to mitigate disruptions.

These changes prompted closer collaboration among manufacturers, distributors, payors, and hospital procurement teams to maintain uninterrupted access. Beyond cost management, the tariff environment accelerated conversations about supply chain resilience and localization, aligning operational decisions with clinical quality objectives—even benefiting innovation through enhanced focus on nearshore manufacturing and value-based contracting.

Methodology & Data Sources

This analysis integrates primary research, including structured interviews with clinical leaders and procurement experts, along with secondary synthesis of literature, regulatory documents, and clinical guidelines. Findings were triangulated with real-world diagnostic workflow comparisons across regions and were validated through expert feedback and scenario analysis.

Why This Report Matters

  • Enables senior executives to understand the clinical, operational, and competitive environment shaping access, innovation, and patient care for rare androgen metabolism disorders.
  • Offers actionable insight into evolving segmentation, distribution strategies, and regulatory variables that affect growth, investment, and procurement planning.
  • Supports the alignment of product development, supply chain strategy, and digital health investment to rapidly changing market demands.

Conclusion

Healthcare leaders who proactively adapt diagnostic, product, and distribution strategies are positioned to navigate evolving expectations and external pressures. The pathway to system-level resilience lies in targeted investment, cross-sector collaboration, and continuous evidence generation for measurable improvements in patient access and outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. 5-Alpha Reductase Deficiency Market, by Treatment Type
8.1. Dutasteride
8.2. Finasteride
9. 5-Alpha Reductase Deficiency Market, by Formulation
9.1. Capsule
9.1.1. Extended Release
9.1.2. Immediate Release
9.2. Solution
9.2.1. Concentrated
9.2.2. Standard
9.3. Tablet
9.3.1. Extended Release
9.3.2. Immediate Release
10. 5-Alpha Reductase Deficiency Market, by Route Of Administration
10.1. Oral
10.2. Topical
11. 5-Alpha Reductase Deficiency Market, by Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. 5-Alpha Reductase Deficiency Market, by Distribution Channel
12.1. Hospital Pharmacy
12.1.1. Private
12.1.2. Public
12.2. Online Pharmacy
12.2.1. Branded Portal
12.2.2. Third-Party Marketplace
12.3. Retail Pharmacy
12.3.1. Chain
12.3.2. Independent
13. 5-Alpha Reductase Deficiency Market, by End User
13.1. Clinics
13.1.1. Dermatology
13.1.2. Urology
13.2. Home Care
13.2.1. Caregiver-Administered
13.2.2. Self-Administered
13.3. Hospitals
13.3.1. General
13.3.2. Specialty
14. 5-Alpha Reductase Deficiency Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. 5-Alpha Reductase Deficiency Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. 5-Alpha Reductase Deficiency Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States 5-Alpha Reductase Deficiency Market
18. China 5-Alpha Reductase Deficiency Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Agilent Technologies, Inc.
19.6. Bio-Rad Laboratories, Inc.
19.7. Cadila Healthcare Limited
19.8. Danaher Corporation
19.9. F. Hoffmann-La Roche AG
19.10. Fulgent Genetics, Inc.
19.11. Illumina, Inc.
19.12. Invitae Corporation
19.13. PerkinElmer, Inc.
19.14. QIAGEN N.V.
19.15. Sun Pharmaceutical Industries Ltd.
19.16. Teva Pharmaceutical Industries Ltd.
19.17. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 184. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 187. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 188. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 189. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 190. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 192. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 194. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 195. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 196. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 198. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 199. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 216. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 218. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 219. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 220. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 221. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 222. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 224. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 226. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 227. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 228. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 230. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 231. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 251. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 252. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 253. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 254. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 255. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 257. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 259. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 260. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 261. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 263. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 264. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 265. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 266. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 267. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 268. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 269. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 270. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 271. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 272. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 273. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 274. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 275. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 276. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 277. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 279. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 280. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 297. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 298. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 299. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 300. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 301. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
TABLE 302. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 303. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 304. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 305. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 307. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 308. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE

Companies Mentioned

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cadila Healthcare Limited
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.56 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.98 Billion
Compound Annual Growth Rate11.2%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

5-Alpha Reductase Deficiency Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

5-Alpha Reductase Deficiency Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
5-Alpha Reductase Deficiency Market Report 2025 - Product Image

5-Alpha Reductase Deficiency Market Report 2025

  • Report
  • 200 Pages
  • Global
From
BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030 - Product Image

BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

  • Report
  • 329 Pages
  • Global
From
5-Alpha Reductase Inhibitor - Pipeline Insight, 2025 - Product Image

5-Alpha Reductase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Recombinant Carbonyl Reductase Market - Global Forecast 2026-2032 - Product Image

Recombinant Carbonyl Reductase Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From

About the 5 Alpha Reductase Deficiency Drugs Market

Alpha Reductase Deficiency Drugs are a class of drugs used to treat a rare genetic disorder known as 5-alpha reductase deficiency. This disorder is characterized by the body's inability to produce the enzyme 5-alpha reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). Without this enzyme, the body is unable to produce DHT, which is essential for normal sexual and reproductive development. As a result, individuals with 5-alpha reductase deficiency may experience a range of symptoms, including incomplete male genitalia, infertility, and an inability to produce sperm. Alpha Reductase Deficiency Drugs are used to treat the symptoms of 5-alpha reductase deficiency by providing the body with the necessary enzyme. These drugs are typically administered orally or through injections, and may be used in combination with other treatments such as hormone replacement therapy. The Alpha Reductase Deficiency Drugs market is an important part of the Sexual and Reproductive Health Drugs market, as it provides a treatment option for individuals with 5-alpha reductase deficiency. This market is expected to grow in the coming years, as more individuals are diagnosed with the disorder and the need for effective treatments increases. Some companies in the Alpha Reductase Deficiency Drugs market include Merck, Pfizer, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.